Similar articles

• Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy.

  Léger B, Cartoni R, Praz M, Lamon S, Dériaz O, Crettenand A, Gobelet C, Rohmer P, Konzelmann M, Luthi F, Russell AP. Léger B, et al. J Physiol. 2006 Nov 1;576(Pt 3):923-33. doi: 10.1113/jphysiol.2006.116715. Epub 2006 Aug 17. J Physiol. 2006. PMID: 16916907 Free PMC article.
• Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease.

  Doucet M, Russell AP, Léger B, Debigaré R, Joanisse DR, Caron MA, LeBlanc P, Maltais F. Doucet M, et al. Am J Respir Crit Care Med. 2007 Aug 1;176(3):261-9. doi: 10.1164/rccm.200605-704OC. Epub 2007 May 3. Am J Respir Crit Care Med. 2007. PMID: 17478621
• Signalling pathways that mediate skeletal muscle hypertrophy and atrophy.

  Glass DJ. Glass DJ. Nat Cell Biol. 2003 Feb;5(2):87-90. doi: 10.1038/ncb0203-87. Nat Cell Biol. 2003. PMID: 12563267 Review.
• Atrogin-1, MuRF1, and FoXO, as well as phosphorylated GSK-3beta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients.

  Léger B, Senese R, Al-Khodairy AW, Dériaz O, Gobelet C, Giacobino JP, Russell AP. Léger B, et al. Muscle Nerve. 2009 Jul;40(1):69-78. doi: 10.1002/mus.21293. Muscle Nerve. 2009. PMID: 19533653
• Molecular determinants of skeletal muscle mass: getting the "AKT" together.

  Nader GA. Nader GA. Int J Biochem Cell Biol. 2005 Oct;37(10):1985-96. doi: 10.1016/j.biocel.2005.02.026. Epub 2005 Mar 21. Int J Biochem Cell Biol. 2005. PMID: 16125108 Review.